Mesut Yılmaz

机构：Inonu University, Istanbul Medipol University · ORCID：0000-0001-8022-7325

发表论文 128 篇 · 总被引 3676 次 · h-index 27

代表论文

• Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study (2023 · Intensive Care Medicine · 被引 262)
• Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial (2022 · The Lancet · 被引 185)
• Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study (2020 · Clinical Infectious Diseases · 被引 163)
• Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2) (2021 · Open Forum Infectious Diseases · 被引 94)
• Switch to oral antibiotics in Gram-negative bacteraemia: a randomized, open-label, clinical trial (2023 · Clinical Microbiology and Infection · 被引 35)
• Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial (2025 · The Lancet Infectious Diseases · 被引 24)